GMP Certified / Ornithine Aspartate Injection 5g/10ml

• Quality Standard: Bp, USP
• Ctd Dossier: Ready
• Documentation: Copp, COA
• Factory Certification: GMP
• Transport Package: Carton
• Specification: 5g/10ml
• Model NO.: injection
• Trademark: Sinolead
• Origin: China
• Production Capacity: 100, 000, 000 Per Year

Product Description

Product Description

Generic Name	Ornithine Aspartate Injection
Strength	5g/10ml
Packing	5 amps/box
Origin	China

Value-added services:
 Packaging design by our team
 Registration service by our team
 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product name:
Ornithine Aspartate Injection

Character:
Light yellow clear liquid

Indications:
Elevated blood ammonia caused by acute and chronic liver diseases (such as various types of hepatitis, cirrhosis, fatty liver, post-hepatitis syndrome) and the treatment of hepatic encephalopathy, such as the potential or episodic hepatic encephalopathy accompanied by or secondary to impaired liver detoxification function (such as cirrhosis), especially for the treatment of the early or hazy state of hepatic coma.

Adverse reactions:
Nausea may occur occasionally, with vomiting in a few cases. In general, the above symptoms are transient and do not need to stop treatment. By reducing the dosage of the drug or slowing down the infusion rate, these adverse reactions can disappear

Pharmacology and toxicology
In the body, ornithine aspartate acts on two major ammonia detoxification pathways - urea synthesis and glutamine synthesis - by producing two amino acids, ornithine and aspartate.
Urea synthesis occurs in hepatocytes around the portal vein. Ornithine is involved in the synthesis of urea from ammonia as both catalyst and substrate for two enzymes, ornithine carbamyltransferase and carbamyl-phosphate synthetase.
The synthesis of glutamine occurs in hepatocytes surrounding the hepatic veins, especially in the pathological state where aspartate and other dicarboxylates, such as metabolites of ornithine, are ingested by hepatocytes surrounding the hepatic veins to synthesize glutamine and bind ammonia in the form of glutamine. In both physiological and pathological conditions, glutamine acts as an amino acid that binds to ammonia, which not only allows ammonia to be excreted in a non-toxic form, but also activates the important urea cycle (i.e., the exchange of glutamine between cells).
In the physiological state, the role of ornithine aspartate is not limited to urea synthesis, animal experiments have found that the increase of glutamine synthesis has the effect of reducing blood ammonia levels, and some clinical trials have also found that they have the effect of improving the ratio of branchchain amino acids and aromatic amino acids.
Rats and dogs were used as subjects to observe the toxicity of ornithine aspartate by intravenous infusion, single and continuous intravenous infusion for 4 weeks. No toxic effects were observed at doses less than 1500 mg/kg body weight.

Storage:
Store below 25 ° C, away from children.